Synteract, Inc. is a full-service contract research organization (CRO) with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Established in 1995 by two veterans of the pharmaceutical industry, Synteract has earned a reputation as a responsive partner to its clients, understanding the unique challenges inherent in performing clinical trials. Its full-service capabilities allow the company to handle an entire program or just specific services needed by clients, from protocol strategy to regulatory submission. Experienced teams support multiple software and technology platforms to deliver clinical trial services cost effectively.
Synteract’s expertise encompasses all levels of clinical research, from early phase I and II trials, to the greater requirements of phase III and IV trials, across a wide range of therapeutic areas, including a notable emphasis in oncology, central nervous system (CNS), cardiovascular disease, respiratory and ophthalmology. Synteract enjoys a high rate of repeat business and referrals from existing clients at more than 90 percent – a testament to its reliability and quality. The company’s standards of integrity and reliability are evident in its history as Synteract has contributed to 23 new products approved by the FDA.
According to CEO Wendel Barr, “At Synteract, what we say is what we do. We truly commit to each client, embracing our corporate philosophy of ‘Shared Work – Shared Vision.’ By providing motivated and knowledgeable staff, customized solutions, quality deliverables, and sound regulatory compliance, we focus together on our clients’ goals, and tailor an approach for each project, to deliver as promised at a competitive price.”
Headquartered in Carlsbad, California with offices in North Carolina and Czech Republic, Synteract currently employs more than 350 professionals in its three offices and
regionally throughout the U.S. Additionally,
it has collaborated with CRO partners worldwide in order to provide outstanding patient cost and time-to-enrollment advantages on an international scale.
Submitted by Synteract, Inc.
5759 Fleet Street, Carlsbad, CA 92008